Clinical Trial: Retlirafusp alfa combined with platinum-based chemotherapy as the first-line treatment for advanced NSCLC with negative driver genes mutations (China)

China, Aug. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Retlirafusp alfa combined with platinum-based chemotherapy as the first-line treatment for advanced NSCLC with negative driver genes mutations'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130414

Registration Time: 2026/08/19

Type: Interventional study

Primary Sponsor: Anhui Provincial Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339101

Published by HT Digital Content Services with permission from Health Daily Digest....